Breast Cancer Index
BIOTHERANOSTICS, INC. A HOLOGIC COMPANY
Breast Cancer Index™ (BCI), performed by Biotheranostics, Inc., is the only test that is guideline-recognized to predict extended anti-estrogen therapy benefit.
A New Standard for Extended Endocrine Therapy Decision-Making
Extending endocrine therapy beyond 5 years has been shown to reduce the risk of recurrence in some women with HR+, early-stage breast cancer. However, longer treatment is associated with significant potential side effects and adverse events, and many women do not benefit.
Breast Cancer Index is a unique, proprietary genomic test that helps inform the appropriate duration of endocrine therapy by reporting two pieces of critical information:
- Is she likely to benefit from extended endocrine therapy?
- What is her individual risk of late distant recurrence (5-10 years post-diagnosis)?
For Breast Cancer Index Intended Use and Limitations, visit the full site.
Biotheranostics, Inc., A Hologic Company
9640 Towne Centre Drive, Suite 200
San Diego, CA 92121
1 (877) 886-6739